Th17/Treg imbalance in murine cystic fibrosis is linked to indoleamine 2,3-dioxygenase deficiency but corrected by kynurenines

American Journal of Respiratory and Critical Care Medicine

Volumn 187, Issue 6, 2013, Pages 609-620

  Iannitti, Rossana G ^a   Carvalho, Agostinho ^a,b,c   Cunha, Cristina ^a   De Luca, Antonella ^a   Giovannini, Gloria ^a   Casagrande, Andrea ^a,d   Zelante, Teresa ^a   Vacca, Carmine ^a   Fallarino, Francesca ^a   Puccetti, Paolo ^a   Massi Benedetti, Cristina ^a   Defilippi, Gloria ^e   Russo, Maria ^e   Porcaro, Luigi ^e   Colombo, Carla ^e,f   Ratclif, Luigi ^g   De Benedictis, Fernando M ^h   Romani, Luigina ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF MINHO   (Portugal)

^c UNIVERSITY OF MINHO   (Portugal)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g Istituto Ospedale G Tatarella   (Italy)

^h Salesi Children's Hospital of Ancona   (Italy)

Author keywords

Aspergillosis; Cystic fibrosis; Indoleamine 2,3 dioxygenase; Th17 Treg balance

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; KYNURENINE; TRANSCRIPTION FACTOR FOXP3; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASPERGILLUS FUMIGATUS; CALCIUM CELL LEVEL; CATABOLISM; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; ENZYME DEFICIENCY; ENZYME DEGRADATION; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNITY; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; IN VIVO STUDY; INFECTION SENSITIVITY; LUNG LAVAGE; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH17 CELL; TRANSCRIPTION REGULATION;

ANIMALS; CYSTIC FIBROSIS; FORKHEAD TRANSCRIPTION FACTORS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KYNURENINE; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; UP-REGULATION;

EID: 84875158201     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201207-1346OC     Document Type: Article

References (65)

1. Ulrich M, Worlitzsch D, Viglio S, Siegmann N, Iadarola P, Shute JK, Geiser M, Pier GB, Friedel G, Barr ML, et al. Alveolar inflammation in cystic fibrosis. J Cyst Fibros 2010;9:217-227.
2. Decraene A, Willems-Widyastuti A, Kasran A, De Boeck K, Bullens DM, Dupont LJ. Elevated expression of both mRNA and protein levels of IL-17A in sputum of stable cystic fibrosis patients. Respir Res 2010;11:177.
3. McAllister F, Henry A, Kreindler JL, Dubin PJ, Ulrich L, Steele C, Finder JD, Pilewski JM, Carreno BM, Goldman SJ, et al. Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-a and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis. J Immunol 2005;175:404-412.
4. Tan HL, Regamey N, Brown S, Bush A, Lloyd CM, Davies JC. The Th17 pathway in cystic fibrosis lung disease. Am J Respir Crit Care Med 2011;184:252-258.
5. Elizur A, Cannon CL, Ferkol TW. Airway inflammation in cystic fibrosis. Chest 2008;133:489-495.
6. Bruscia EM, Zhang PX, Ferreira E, Caputo C, Emerson JW, Tuck D, Krause DS, Egan ME. Macrophages directly contribute to the exaggerated inflammatory response in cystic fibrosis transmembrane conductance regulator-/- mice. Am J Respir CellMol Biol 2009;40:295-304.
7. Chmiel JF, Berger M, Konstan MW. The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol 2002; 23:5-27.
8. Klein M, Cohen-Cymberknoh M, Armoni S, Shoseyov D, Chisin R, Orevi M, Freedman N, Kerem E. 18F-fluorodeoxyglucose-PET/CT imaging of lungs in patients with cystic fibrosis. Chest 2009;136: 1220-1228.
9. Romani L, Zelante T, De Luca A, Fallarino F, Puccetti P. IL-17 and therapeutic kynurenines in pathogenic inflammation to fungi. J Immunol 2008;180:5157-5162.
10. Puccetti P, Grohmann U. IDO and regulatory T cells: a role for reverse signalling and non-canonical Nf-κB activation. Nat Rev Immunol 2007; 7:817-823.
11. Romani L, Fallarino F, De Luca A, Montagnoli C, D'Angelo C, Zelante T, Vacca C, Bistoni F, Fioretti MC, Grohmann U, et al. Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature 2008;451:211-215.
12. Delhaes L, Monchy S, Frealle E, Hubans C, Salleron J, Leroy S, Prevotat A, Wallet F, Wallaert B, Dei-Cas E, et al. The airway microbiota in cystic fibrosis: a complex fungal and bacterial community - implications for therapeutic management. PLoS One 2012;7:e36313.
13. Knutsen AP, Bush RK, Demain JG, Denning DW, Dixit A, Fairs A, Greenberger PA, Kariuki B, Kita H, Kurup VP, et al. Fungi and allergic lower respiratory tract diseases. J Allergy Clin Immunol 2012; 129:280-291; quiz 292-283.
14. Sudfeld CR, Dasenbrook EC, Merz WG, Carroll KC, Boyle MP. Prevalence and risk factors for recovery of filamentous fungi in individuals with cystic fibrosis. J Cyst Fibros 2010;9:110-116.
15. de Vrankrijker AM, van der Ent CK, van Berkhout FT, Stellato RK, Willems RJ, Bonten MJ, Wolfs TF. Aspergillus fumigatus colonization in cystic fibrosis: implications for lung function? Clin Microbiol Infect 2011;17:1381-1386.
16. Stevens DA, Moss RB, Kurup VP, Knutsen AP, Greenberger P, Judson MA, Denning DW, Crameri R, Brody AS, Light M, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis - state of the art: Cystic Fibrosis Foundation consensus conference. Clin Infect Dis 2003;37(Suppl 3):S225-S264.
17. Mastella G, Rainisio M, Harms HK, Hodson ME, Koch C, Navarro J, Strandvik B, McKenzie SG. Allergic bronchopulmonary aspergillosis in cystic fibrosis. Eur Respir J 2001;17:1052-1053.
18. Palmer LB, Greenberg HE, Schiff MJ. Corticosteroid treatment as a risk factor for invasive aspergillosis in patients with lung disease. Thorax 1991;46:15-20.
19. Iken K, Liu K, Liu H, Bizargity P, Wang L, Hancock WW, Visner GA. IDO and metabolites protect mouse lung allografts and impair calcium mobilization of T cells. Am J Respir Cell Mol Biol 2012;47:405-416.
20. Antigny F, Norez C, Becq F, Vandebrouck C. Calcium homeostasis is abnormal in cystic fibrosis airway epithelial cells but is normalized after rescue of F508del-CFTR. Cell Calcium 2008;43:175-183.
21. Bragonzi A. Murine models of acute and chronic lung infection with cystic fibrosis pathogens. Int J Med Microbiol 2010;300:584-593.
22. Iannitti RG, Carvalho A, De Luca A, Giovannini G, Casagrande A, Cunha C, De Benedictis FM, Romani L. Cystic fibrosis Th17/Treg imbalance to Aspergillus fumigatus: insights for novel anti-inflammatory strategies and immunogenetic screening [abstract]. In: Chernick V, editor. The 26th Annual North American Cystic Fibrosis Conference. Pediatr Pulmonol 2012;47:338.
23. Zhou L, Dey CR, Wert SE, DuVall MD, Frizzell RA, Whitsett JA. Correction of lethal intestinal defect in a mouse model of cystic fibrosis by human CFTR. Science 1994;266:1705-1708.
24. Bonifazi P, Zelante T, D'Angelo C, De Luca A, Moretti S, Bozza S, Perruccio K, Iannitti RG, Giovannini G, Volpi C, et al. Balancing inflammation and tolerance in vivo through dendritic cells by the commensal Candida albicans. Mucosal Immunol 2009;2:362-374.
25. Montagnoli C, Fallarino F, Gaziano R, Bozza S, Bellocchio S, Zelante T, Kurup WP, Pitzurra L, Puccetti P, Romani L. Immunity and tolerance to Aspergillus involve functionally distinct regulatory T cells and tryptophan catabolism. J Immunol 2006;176:1712-1723.
26. Galietta LJ, Folli C, Marchetti C, Romano L, Carpani D, Conese M, Zegarra-Moran O. Modification of transepithelial ion transport in human cultured bronchial epithelial cells by interferon-g. Am J Physiol Lung Cell Mol Physiol 2000;278:L1186-L1194.
27. de Luca A, Bozza S, Zelante T, Zagarella S, D'Angelo C, Perruccio K, Vacca C, Carvalho A, Cunha C, Aversa F, et al. Non-hematopoietic cells contribute to protective tolerance to Aspergillus fumigatus via a TRIF pathway converging on IDO. Cell Mol Immunol 2010;7:459-470.
28. Schrocksnadel K, Wirleitner B, Winkler C, Fuchs D. Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta 2006;364:82-90.
29. Di A, Brown ME, Deriy LV, Li C, Szeto FL, Chen Y, Huang P, Tong J, Naren AP, Bindokas V, et al. CFTR regulates phagosome acidification in macrophages and alters bactericidal activity.Nat Cell Biol 2006;8:933-944.
30. Gessner MA, Werner JL, Lilly LM, Nelson MP, Metz AE, Dunaway CW, Chan YR, Ouyang W, Brown GD, Weaver CT, et al. Dectin-1-dependent interleukin-22 contributes to early innate lung defense against Aspergillus fumigatus. Infect Immun 2012;80:410-417.
31. Chan YR, Chen K, Duncan SR, Lathrop KL, Latoche JD, Logar AJ, Pociask DA, Wahlberg BJ, Ray P, Ray A, et al. Patients with cystic fibrosis have inducible IL-17+IL-22+ memory cells in lung draining lymph nodes. J Allergy Clin Immunol (In press)
32. Qiu J, Heller JJ, Guo X, Chen ZM, Fish K, Fu YX, Zhou L. The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. Immunity 2012;36:92-104.
33. Romani L. Immunity to fungal infections. Nat Rev Immunol 2011;11:275-288.
34. Allard JB, Poynter ME, Marr KA, Cohn L, Rincon M, Whittaker LA. Aspergillus fumigatus generates an enhanced Th2-biased immune response in mice with defective cystic fibrosis transmembrane conductance regulator. J Immunol 2006;177:5186-5194.
35. Mueller C, Braag SA, Keeler A, Hodges C, Drumm M, Flotte TR. Lack of cystic fibrosis transmembrane conductance regulator in CD3+ lymphocytes leads to aberrant cytokine secretion and hyperinflammatory adaptive immune responses. Am J Respir Cell Mol Biol 2011;44:922-929.
36. Kreindler JL, Steele C, Nguyen N, Chan YR, Pilewski JM, Alcorn JF, VyasYM, Aujla SJ, Finelli P, BlanchardM, et al. VitaminD3 attenuates Th2 responses to Aspergillus fumigatus mounted by CD4+T cells from cystic fibrosis patients with allergic bronchopulmonary aspergillosis. J Clin Invest 2010;120:3242-3254.
37. Fric J, Lim CX, Koh EG, Hofmann B, Chen J, Tay HS, Mohammad Isa SA, Mortellaro A, Ruedl C, Ricciardi-Castagnoli P. Calcineurin/ NFAT signalling inhibits myeloid haematopoiesis. EMBO Mol Med 2012;4:269-282.
38. Grohmann U, Fallarino F, Bianchi R, Orabona C, Vacca C, Fioretti MC, Puccetti P. A defect in tryptophan catabolism impairs tolerance in nonobese diabetic mice. J Exp Med 2003;198:153-160.
39. Chmiel JF, Konstan MW. Anti-inflammatory medications for cystic fibrosis lung disease: selecting the most appropriate agent. Treat Respir Med 2005;4:255-273.
40. de Benedictis FM, Bush A. Corticosteroids in respiratory diseases in children. Am J Respir Crit Care Med 2012;185:12-23.
41. Jubin V, Ranque S, Stremler Le Bel N, Sarles J, Dubus JC. Risk factors for Aspergillus colonization and allergic bronchopulmonary aspergillosis in children with cystic fibrosis. Pediatr Pulmonol 2010;45:764-771.
42. Pressler T. Targeting airway inflammation in cystic fibrosis in children: past, present, and future. Paediatr Drugs 2011;13:141-147.
43. Knutsen AP, Slavin RG. Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis. Clin Dev Immunol 2011;2011:843763.
44. Carvalho A, Pasqualotto AC, Pitzurra L, Romani L, Denning DW, Rodrigues F. Polymorphisms in Toll-like receptor genes and susceptibility to pulmonary aspergillosis. J Infect Dis 2008;197:618-621.
45. Guilbault C, Wojewodka G, Saeed Z, Hajduch M, Matouk E, De Sanctis JB, Radzioch D. Cystic fibrosis fatty acid imbalance is linked to ceramide deficiency and corrected by fenretinide. Am J Respir Cell Mol Biol 2009; 41:100-106.
46. Gammelsrud KW, Sandven P, Hoiby EA, Sandvik L, Brandtzaeg P, Gaustad P. Colonization by Candida in children with cancer, children with cystic fibrosis, and healthy controls. Clin Microbiol Infect 2011; 17:1875-1881.
47. Zelante T, De Luca A, Bonifazi P, Montagnoli C, Bozza S, Moretti S, Belladonna ML, Vacca C, Conte C, Mosci P, et al. IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol 2007;37:2695-2706.
48. Zelante T, Iannitti RG, De Luca A, Arroyo J, Blanco N, Servillo G, Sanglard D, Reichard U, Palmer GE, Latge JP, et al. Sensing of mammalian IL-17A regulates fungal adaptation and virulence. Nat Commun 2012;3:683.
49. Roussel L, Rousseau S. IL-17 primes airway epithelial cells lacking functional cystic fibrosis transmembrane conductance regulator (CFTR) to increase NOD1 responses. Biochem Biophys Res Commun 2010;391: 505-509.
50. Tang A, Sharma A, Jen R, Hirschfeld AF, Chilvers MA, Lavoie PM, Turvey SE. Inflammasome-mediated IL-1b production in humans with cystic fibrosis. PLoS One 2012;7:e37689.
51. Dubin PJ, Kolls JK. IL-17 in cystic fibrosis: more than just Th17 cells. Am J Respir Crit Care Med 2011;184:155-157.
52. Grohmann U, Volpi C, Fallarino F, Bozza S, Bianchi R, Vacca C, Orabona C, Belladonna ML, Ayroldi E, Nocentini G, et al. Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nat Med 2007;13:579-586.
53. Casaulta C, Schoni MH, Weichel M, Crameri R, Jutel M, Daigle I, Akdis M, Blaser K, Akdis CA. IL-10 controls Aspergillus fumigatus- and Pseudomonas aeruginosa-specific T-cell response in cystic fibrosis. Pediatr Res 2003;53:313-319.
54. Brouard J, Knauer N, Boelle PY, Corvol H, Henrion-Caude A, Flamant C, Bremont F, Delaisi B, Duhamel JF, Marguet C, et al. Influence of interleukin-10 on Aspergillus fumigatus infection in patients with cystic fibrosis. J Infect Dis 2005;191:1988-1991.
55. Mueller C, Braag SA, Martino AT, Tang Q, Campbell-Thompson M, Flotte TR. The pros and cons of immunomodulatory IL-10 gene therapy with recombinant AAV in a Cftr-/-dependent allergy mouse model. Gene Ther 2009;16:172-183.
56. Chaudhary N, Datta K, Askin FB, Staab JF, Marr KA. Cystic fibrosis transmembrane conductance regulator regulates epithelial cell response to Aspergillus and resultant pulmonary inflammation. Am J Respir Crit Care Med 2012;185:301-310.
57. Tsuda K, Yamanaka K, Kitagawa H, Akeda T, Naka M, Niwa K, Nakanishi T, Kakeda M, Gabazza EC, Mizutani H. Calcineurin inhibitors suppress cytokine production from memory T cells and differentiation of naive T cells into cytokine-producing mature T cells. PLoS One 2012;7:e31465.
58. Tesse R, Manca A, Abrusci MR, Pinto S, Leonetti G, De Robertis S, Cavallo L, De Robertis F. The role of post-transplantation cyclosporine treatment in the course of cystic fibrosis pulmonary disease: a case report. Immunopharmacol Immunotoxicol 2012;34:714-716.
59. Steinbach WJ, Reedy JL, Cramer RA Jr, Perfect JR, Heitman J. Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections. Nat Rev Microbiol 2007;5:418-430.
60. Ramsey BW, Banks-Schlegel S, Accurso FJ, Boucher RC, Cutting GR, Engelhardt JF, Guggino WB, Karp CL, Knowles MR, Kolls JK, et al. Future directions in early cystic fibrosis lung disease research. Am J Respir Crit Care Med 2012;185:887-892.
61. Cohen-Cymberknoh M, Shoseyov D, Kerem E. Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med 2011;183:1463-1471.
62. Pier GB. The challenges and promises of new therapies for cystic fibrosis. J Exp Med 2012;209:1235-1239.
63. Aaron SD, Vandemheen KL, Freitag A, Pedder L, Cameron W, Lavoie A, Paterson N, Wilcox P, Rabin H, Tullis E, et al. Treatment of Aspergillus fumigatus in patients with cystic fibrosis: a randomized, placebo-controlled pilot study. PLoS One 2012;7:e36077.
64. Elphick HE, Southern KW. Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev 2012;6:CD002204.
65. Amorim A, Guedes-Vaz L, Araujo R. Susceptibility to five antifungals of Aspergillus fumigatus strains isolated from chronically colonised cystic fibrosis patients receiving azole therapy. Int J Antimicrob Agents 2010;35:396-399.